VistaGen Therapeutics's Dividends per Share for the
three
months ended in Mar. 2022 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
VistaGen Therapeutics Dividend Yield % Historical Data
The historical data trend for VistaGen Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Dividend Yield %
-
-
-
-
-
VistaGen Therapeutics Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Dividend Yield %
-
-
-
-
-
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics Dividend Yield % Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
VistaGen Therapeutics Dividend Yield % Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.01(0.9%) Volume: 900,049 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
